The introduction of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable buzz within the medical community. This groundbreaking dual GIP and GLP-1 agonist medication suggests to provide significant improvements in fat shedding compared to existing therapies. Early patient data have indicated significant decreases in body mass , c